Innovative Nanobody-Enabled NTRK2/TFRC Targeting for Neurodegeneration Therapeutics

VHH-P662 is a next-generation humanized nanobody fusion construct designed to target both neurotrophic receptor tyrosine kinase 2 (NTRK2) and transferrin receptor (TFRC). Currently in the Biological Testing development phase, VHH-P662 holds significant promise for the treatment of neurodegeneration. Leveraging dual targeting of two well-validated proteins involved in neuronal signaling and blood-brain barrier transport, this molecule is structured to address critical challenges in central nervous system therapies. The construct combines an IgG1 kappa agonist targeting NTRK2 with a single-domain antibody against TFRC, enabling efficient brain delivery and potent biological activity for potential neuroprotective applications.

Licensing Opportunity

VHH-P662 is actively open for out-licensing and strategic partnerships. We welcome inquiries from pharmaceutical companies and investors interested in advancing this promising neurodegeneration therapeutic.

Development Phase

Modality

VHH-P662 employs a modular fusion construct combining a chimeric IgG1 kappa agonist antibody with a single-domain nanobody, expressed in Chinese hamster ovary cells. The unique structural format leverages a single-domain antibody for TFRC binding inserted between IgG1 heavy chain domains via flexible linkers, coupled with NTRK2 targeting. This design equips VHH-P662 with key attributes such as low molecular weight, enhanced tissue penetration, and robust biochemical stability. The nanobody component facilitates efficient blood-brain barrier traversal via TFRC-mediated uptake, while the IgG1 kappa agonist core retains effector functionality, collectively optimizing therapeutic engagement in neurodegeneration.

Target

NTRK2 is a receptor tyrosine kinase critical for neuronal survival and synaptic plasticity, highly expressed in the central nervous system. TFRC, a transmembrane glycoprotein, serves as a major iron uptake receptor, and is ubiquitously present, particularly in brain endothelial cells comprising the blood-brain barrier. Both NTRK2 and TFRC are attractive targets in neurodegeneration: NTRK2 modulation supports neurotrophic signaling that may enhance neuroresilience, while TFRC enables strategic delivery of biologics across the blood-brain barrier. VHH-P662’s simultaneous targeting of NTRK2 and TFRC provides dual strategic value—therapeutic neurotrophic activation and improved brain accessibility—positioning the molecule competitively for next-generation neurodegeneration therapies.

Mechanism of Action

VHH-P662 operates via dual engagement of NTRK2 and TFRC. By agonizing NTRK2, the construct activates downstream signaling pathways associated with neuronal survival and differentiation. The anti-TFRC nanobody moiety intercalated within the antibody structure facilitates receptor-mediated transcytosis across the blood-brain barrier, enhancing central nervous system bioavailability. This architecture enables the molecule to efficiently reach brain targets while modulating key neurotrophic pathways. Moreover, nanobody technologies underpin VHH-P662, providing flexibility for further adaptation—such as the development of multispecific constructs or conjugates—making the platform suitable for wider therapeutic applications beyond neurodegeneration.

Neurodegeneration

Neurodegeneration encompasses a group of debilitating disorders, notably characterized by progressive loss of neuronal structure and function. Globally, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis represent a mounting healthcare burden, particularly as populations age. Existing treatment modalities include small molecule drugs, disease-modifying therapies, and symptomatic agents, with biologics increasingly explored for disease interception. However, most interventions provide limited efficacy, often hindered by inadequate blood-brain barrier penetration and suboptimal target engagement. There remains a tremendous unmet need for therapies offering robust neuroprotection and disease modification. VHH-P662, through its dual targeting capability and engineered brain penetration, holds distinct potential to meet these clinical gaps and advance the treatment landscape for neurodegeneration.